Ua kūpono paha ʻoe iā Tirzepatide a i ʻole Retatrutide?

E kōkua kēia ʻatikala iā ʻoe e koho i kahi āu e kūpono ai ma ka pane ʻana i kēia mau nīnau:

1. He aha ka ʻokoʻa ma waena o tirzepatide a me retatrutide?

2. He aha nā pōmaikaʻi o ka tirzepatide?

3. He aha nā pōmaikaʻi o ka retatrutide?

4. Hoʻohālikelike i nā pono o Retatrutide a me Tirzepatide

He aha ka ʻokoʻa ma waena o tirzepatide a me retatrutide?

ʻO ka ʻokoʻa nui ma waena o tirzepatide a me retatrutide i loko o kā lākou ʻano.ʻO Tirzepatide kahi hui o ʻekolu mau mea hana - liraglutide, kahi glucagon-like peptide-1 agonist (GLP-1);he analogue o ka oxyntomodulin;a me kahi analogue GLP-2.ʻO ka Retarutide, ma ka ʻaoʻao ʻē aʻe, ua haku ʻia i hoʻokahi mea hana - exenatide, kahi GLP-1 ʻē aʻe i hōʻike nui ʻia i ka pancreas.Hoʻohana ʻia nā lāʻau ʻelua e mālama i ka maʻi diabetes type 2 ma o ka hoʻonui ʻana i ka hana insulin a me ka hoʻohaʻahaʻa ʻana i nā pae glucose koko.Eia nō naʻe, ua hōʻike ʻia ka retarutide e hōʻemi i ka ʻai ʻoi aku ka maikaʻi ma mua o ka tirzepatide wale nō ma muli o kona hopena i nā hormone i pili i ka pōloli a me ka māʻona.No laila, hiki ke hoʻohana ʻia ma ke ʻano o ka hoʻopili ʻana i ka hoʻokele paona no nā poʻe me ka maʻi maʻi i ke kaumaha a i ʻole ka momona.

He aha nā pōmaikaʻi o ka tirzepatide?

①Hoʻomaikaʻi i ka mana glycemic a me nā pae A1C, e alakaʻi ana i ke olakino holoʻokoʻa

Tirzepatide, he glucagon-like peptide 1 receptor agonist a me GLP-1/glucose-dependent insulinotropic polypeptide (GIP) dual agonist, he koho lapaʻau hou no ka maʻi diabetes type 2.Ua ʻike ʻia ʻoi aku ka maikaʻi ma mua o ka retatrutide i ka hoʻomaikaʻi ʻana i ka mana glycemic a me nā pae A1C.I nā hoʻokolohua lapaʻau, pili ka tirzepatide me ka hoʻohaʻahaʻa nui ʻana i nā pae A1C i nā wiki 12 i hoʻohālikelike ʻia me ka retatrutide (-2.3% vs -1.8%), e alakaʻi ana i nā hopena olakino maikaʻi loa no nā maʻi.

②Hoʻemi ʻia ka pilikia o nā hanana cardiovascular e like me ka hōʻeha puʻuwai a me ka hahau ʻana

Hāʻawi ʻo Tirzepatide i ka nui o nā pono kūpono no ka poʻe i pilikia no nā hanana cardiovascular e like me ka hōʻeha puʻuwai a me ka hahau.Ua ʻike ʻia kahi noiʻi 2019 i paʻi ʻia ma ka puke pai ʻo The Lancet i ka poʻe e lawe ana i ka tirzepatide he haʻahaʻa haʻahaʻa loa o nā hanana cardiovascular adverse nui (MACE) i hoʻohālikelike ʻia i ka poʻe e lawe ana i ka retatrutide.Hoʻopili kēia i kahi hōʻemi 35% i ka MACE i hoʻohālikelike ʻia me ka retatrutide, ʻaʻole i hōʻike i ka ʻokoʻa koʻikoʻi i ka hopena i nā pilikia cardiovascular.I ka wā o ke aʻo ʻana, ua ʻike nā mea noiʻi ua ʻike nā mea maʻi e lawe ana i ka tirzepatide i nā haʻahaʻa haʻahaʻa o ka maʻi coronary artery, myocardial infarction, congestive heart failure and stroke ma mua o ka poʻe i loko o ka hui retatrutide.Eia kekahi, ua hōʻike pū nā poʻe i lawe i ka tirzepatide i ka hoʻomaikaʻi ʻana i ke kiʻekiʻe o ke kō koko koko a me ka liʻiliʻi o ke kaumaha ma mua o ka poʻe e lawe ana i ka retatrutide.ʻO ka mea hope loa, pono e hoʻomaopopo ʻia ʻaʻole pale wale ʻia ka poʻe e lawe ana i ka tirzepatide mai ka MACE akā ua emi pū kekahi i nā pae HbA1c (kahi hōʻailona no ka pōʻino maʻi diabetes lōʻihi) a me ka pākēneka momona o ke kino ke hoʻohālikelike ʻia i nā pae kumu.ʻO ka mea hope loa, kuhikuhi kēia mau hopena i ka hiki o ka tirzepatide e hōʻemi i nā hanana cardiovascular e pili ana i ka maʻi diabetes type 2 a hāʻawi i nā pono hou e pili ana i ke ʻano o ke kino.

ʻO ke kaumaha o ke kino haʻahaʻa i hoʻohālikelike ʻia me ka retatrutide, hiki ke kōkua i ka hōʻemi ʻana i ka pilikia o nā maʻi pili i ka momona
He nui nā pōmaikaʻi o Tirzepatide i hoʻohālikelike ʻia me ka retatrutide, ʻoi aku ka nui o ke kaumaha o ke kino.Ua ʻike nā haʻawina e hiki i ka tirzepatide ke hoʻemi nui i ke kaumaha o ke kino ma mua o ka retatrutide i ka wā lōʻihi.Hiki ke hoʻopili ʻia kēia i kona hiki ke hoʻoulu i ka hana receptor GLP-1 a hoʻoikaika i ka māʻona.Eia kekahi, ua ʻike ʻia ʻo tirzepatide e hōʻemi i ka momona o ka ʻōpū ma mua o ka retatrutide, hiki ke kōkua i ka hōʻemi ʻana i ka hopena o ka maʻi diabetes, nā maʻi cardiovascular, a me nā maʻi pili i ka momona.Eia kekahi, ua hōʻike ʻia ʻo tirzepatide e hōʻemi i ke kiʻekiʻe o ke kō koko ma mua o ka retatrutide.Hiki i kēia mau hopena ke hoʻomaikaʻi i nā hopena olakino holoʻokoʻa e pili ana i ka momona a me ka metabolic dysfunction.

③Hoʻonui ʻia nā pae ikehu ma muli o ka hoʻomaikaʻi ʻana i ka metabolism glucose

ʻO kekahi o nā pōmaikaʻi nui o ka lawe ʻana i ka tirzepatide ʻo kona hiki ke hoʻonui i nā pae ikehu ma muli o ka hoʻomaikaʻi ʻana i ka metabolism glucose.ʻO kēia ke kumu no ka hana ʻana o GLP1 receptor agonists e like me tirzepatide ma ka hoʻoulu ʻana i ka hoʻokuʻu ʻana o ka insulin i ka pane ʻana i ke kiʻekiʻe o ke kō koko koko.Ma ka hoʻonui ʻana i ka hana insulin a me ka hoʻomaikaʻi ʻana i ka metabolism glucose, hiki i ke kino ke hoʻohana hou aku i ka glucose no ka wahie a hiki i kēia ke alakaʻi i ka piʻi ʻana o ka ikehu.Eia kekahi, hiki i ka GLP1 receptor agonists ke hōʻemi i ka makemake, e alakaʻi ana i ka hōʻemi ʻana i ka makemake meaʻai a hoʻomaikaʻi i ka hoʻokele kaumaha.

He aha nā pōmaikaʻi o ka retatrutide?

Retatrutidehe lāʻau injectable lōʻihi i hoʻohana ʻia e mālama i ka maʻi diabetes type 2.Ua ʻae ʻia e ka US Food and Drug Administration (FDA) no kēia kumu.He nui nā pōmaikaʻi o ka retatrutide, e lilo ia i koho maikaʻi ma waena o nā lāʻau maʻi diabetes ʻē aʻe.

No ka hoʻomaka ʻana, hana wikiwiki ʻo retatrutide i ka wā i hoʻopaʻa ʻia ai a hiki ke ʻike ʻia kona hopena i loko o 24 mau hola o ka lawelawe ʻana.ʻOi aku ka wikiwiki o ka hana ʻana ma mua o nā injectable lōʻihi e like me tirzepatide, a hiki ke lawe i kekahi mau pule ma mua o ka ʻike ʻia ʻana o nā hopena i ʻike ʻia i nā pae kō koko.
Eia hou, ua hōʻike ʻia nā haʻawina e hiki i ka retatrutide ke hōʻemi i nā pae A1C i nā poʻe me ka maʻi maʻi type 2 ke lawe pū ʻia me nā loli ʻai a me nā hoʻoikaika kino.Ua hōʻike pū ʻia nā hoʻokolohua lapaʻau e kōkua ka retatrutide e hōʻemi i ka pae glucose wikiwiki a me ka mana glycemic holoʻokoʻa i nā mea hoʻohana e like me ka placebo.I kekahi mau manawa, ua loaʻa i nā poʻe i loaʻa ʻole ka pōmaikaʻi mai nā lāʻau maʻi diabetes waha i nā hopena maikaʻi me ka retatrutide therapy.

ʻO ka mea hope loa, ʻo kekahi o nā pōmaikaʻi nui loa o ka retatrutide ʻo ia ka maʻalahi o ka hoʻoponopono ʻana;pono ʻo ia i hoʻokahi injection i kēlā me kēia pule ma mua o ka nui o nā injections i kēlā me kēia lā e like me nā lāʻau maʻi diabetes ʻē aʻe.Hiki i kēia ke maʻalahi ka mālama ʻana i kāu maʻi diabetes a kōkua i ka hoʻomaikaʻi ʻana i ka mālama ʻana o ka maʻi i ka hoʻolālā lapaʻau i ka manawa.

Hoʻohālikelike i nā pono o Retatrutide a me Tirzepatide

I ka hiki ana i ka pono, ua hōʻike ʻia ka retatrutide e hōʻemi i nā pae HbA1c e 1.9-2.4%, hoʻohālikelike ʻia me Tirzepatide e hoʻemi ana i nā pae HbA1c e 1.5-2%.Loaʻa i nā lāʻau ʻelua nā hopena ʻaoʻao like, e like me ka nausea a me ke poʻo.Eia naʻe, hiki i kekahi poʻe ke ʻike i ka liʻiliʻi o nā hopena ʻaoʻao me Retatrutide ma mua o Tirzepatide ma muli o kāna mau koi haʻahaʻa haʻahaʻa.

Ma keʻano o ka palekana, ʻae maikaʻi ʻia ka retarutide i ka wā i hoʻohana ʻia i nā koina i manaʻo ʻia a ʻaʻole e hoʻonui i ka pilikia o ka hypoglycemia a i ʻole e hoʻonui i ke kaumaha e like me nā lāʻau lapaʻau ʻē aʻe.Ma ka ʻaoʻao ʻē aʻe, lawe ʻo Tirzepatide i kahi kiʻekiʻe kiʻekiʻe o ka hopena o ka wahi injection ma muli o kona nui nui.Eia kekahi, inā lawe ʻia i ka nui o nā koina hiki ke hoʻoulu i ka hypoglycemia koʻikoʻi a me ka piʻi paona.

I ka hōʻuluʻulu ʻana, ʻo ka retarutide a me ka tirzepatide nā koho kūpono no ka mālama ʻana i ka maʻi maʻi type 2 akā ʻoi aku ka maikaʻi o kekahi no kekahi mau maʻi ma muli o ko lākou pono pilikino.Hāʻawi ʻo Retarutide i ka maikaʻi maikaʻi me ka liʻiliʻi o nā hopena ʻaoʻao ʻoiai ʻoi aku ka palekana ma nā kau i ʻōlelo ʻia;akā naʻe, hiki iā Tirzepatide ke hāʻawi i nā hōʻemi nui aʻe i nā pae HbA1c akā hiki ke lawe i kahi pilikia kiʻekiʻe o nā hopena koʻikoʻi inā ʻaʻole hoʻohana pono ʻia.ʻO ka hope, he mea nui e kūkākūkā me kāu kauka i mea e hoʻoholo ai i kahi koho lapaʻau i kūpono iā ʻoe ma muli o kou kūlana kūikawā a me nā pahuhopu olakino.

E hoʻomaka i kāu tirzepatide a me semaglutide therapy ma LianFu